Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant

Nutrition Journal

Volumn 11, Issue 1, 2012, Pages

  Heppenstall, Charlotte ^a   Bunce, Susan ^a   Smith, Jamie C ^a  

^a TORBAY HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Dietary assessment; Dietary intervention; Drug interventions

Indexed keywords

CANNABINOID 1 RECEPTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; RIMONABANT; TRACE ELEMENT;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; DIET THERAPY; FAT INTAKE; FEMALE; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; MACRONUTRIENT; MALE; METABOLIC RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN INTAKE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE; CANNABINOID RECEPTOR ANTAGONISTS; DIABETES MELLITUS, TYPE 2; DIET; DIETARY CARBOHYDRATES; DIETARY FATS; ENERGY INTAKE; FEMALE; HUMANS; INTERVENTION STUDIES; MALE; MICRONUTRIENTS; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; REGRESSION ANALYSIS; WEIGHT LOSS;

EID: 84867794234     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-11-50     Document Type: Article

References (20)

1. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50years and older. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Diabetes 2003 52 1210 1214 10.2337/diabetes.52.5.1210 12716754 (Pubitemid 36523358)
2. A potential decline in life expectancy in the United States in the 21st century. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS, N Engl J Med 2005 352 1138 1145 10.1056/NEJMsr043743 15784668 (Pubitemid 40365358)
3. Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective. Buyken AE, Mitchell P, Ceriello A, Brand-Miller J, Diabetologia 2010 53 406 418 10.1007/s00125-009-1629-8 20049415
4. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Pagotto U, Pasquali R, Lancet 2005 365 1363 1364 10.1016/S0140-6736(05)66348-9 15836868 (Pubitemid 40523718)
5. A critical review of the cannabinoid receptor as a drug target for obesity management. Akbas F, Gasteyger C, Sjödin A, Astrup A, Larsen TM, Obes Rev 2009 10 58 67 10.1111/j.1467-789X.2008.00520.x 18721231
6. RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, Lancet 2006 368 1660 1672 10.1016/S0140-6736(06)69571-8 17098084 (Pubitemid 46048528)
7. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W, Endocrinology 2008 149 2557 2566 10.1210/en.2007-1515 18276749 (Pubitemid 351574492)
8. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Simiand J, Keane M, Keane PE, Soubrié P, Behav Pharmacol 1998 9 179 181 10065938 (Pubitemid 28186515)
9. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Gessa GL, Orr A, Lai P, Maccioni P, Lecca R, Lobina C, Carai MA, Colombo G, Psychopharmacology (Berl) 2006 185 248 254 10.1007/s00213-006-0327-1 (Pubitemid 43363621)
10. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Elhayany A, Lustman A, Abel R, Attal-Singer J, Vinker S, Diabetes Obes Metab 2010 12 204 209 10.1111/j.1463-1326.2009.01151.x 20151996
11. Carbohydrate for weight and metabolic control: where do we stand? Acheson KJ, Nutrition 2010 26 141 145 10.1016/j.nut.2009.07.002 20122538
12. Effect of high protein vs high carbohydrate intake on insulin sensitivity, body weight, hemoglobin A1c, and blood pressure in patients with type 2 diabetes mellitus. Sargrad KR, Homko C, Mozzoli M, Boden G, J Am Diet Assoc 2005 105 573 580 10.1016/j.jada.2005.01.009 15800559 (Pubitemid 40432389)
13. Effect of a high protein, low carbohydrate diet on blood glucose control in people with type 2 diabetes. Gannon MC, Nuttall FQ, Diabetes 2004 53 2375 2382 10.2337/diabetes.53.9.2375 15331548 (Pubitemid 39145592)
14. Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study. Evangelista LS, Heber D, Li Z, Bowerman S, Hamilton MA, Fonarow GC, J Cardiovasc Nurs 2009 24 207 215 19390338
15. Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. Kirk JK, Graves DE, Craven TE, Lipkin EW, Austin M, Margolis KL, J Am Diet Assoc 2008 108 91 100 10.1016/j.jada.2007.10.003 18155993 (Pubitemid 350296011)
16. The diabetes excess weight loss (DEWL) trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2years in type 2 diabetes. Krebs JD, Elley CR, Parry-Strong A, Lunt H, Drury PL, Bell DA, Robinson E, Moyes SA, Mann JI, Diabetologia 2012 55 905 914 10.1007/s00125-012- 2461-0 22286528
17. Nelson M, Atkinson M, Meyer J, A Photographic Atlas of Food Portion Sizes London: MAFF Publications 1997
18. Cannabinoid physiology and pharmacology: 30 years of progress. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ, Neuropharmacology 2004 47 Suppl 1 345 358 15464149 (Pubitemid 39298276)
19. Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. Mathes CM, Ferrara M, Rowland NE, Am J Physiol Regul Integr Comp Physiol 2008 295 67 R75 10.1152/ajpregu.00150.2008 18448611
20. Endocannabinoids in the regulation of appetite and body weight. Kirkham TC, Behav Pharmacol 2005 16 297 313 10.1097/00008877-200509000-00004 16148436 (Pubitemid 41404803)